XADAGO市場：市場規模、予測、市場洞察-2032年

今後数年間で、パーキンソン病の市場シナリオは、世界中の広範な調査と医療費の増加により変化します。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、XADAGOの優位性に影響を与える可能性のある機会を模索しています。

パーキンソン病に対する他の新興製品は、XADAGOに厳しい市場競争をもたらすと予想され、近い将来、後発の新興治療薬が発売されれば、市場に大きな影響を与えると思われます。

XADAGOがパーキンソン病において効果を発揮する正確なメカニズムは不明です。XADAGOはモノアミン酸化酵素B（MAO-B）の阻害剤です。MAO-Bの活性を阻害することにより、ドーパミンの異化が阻害され、ドーパミンの濃度が上昇し、脳内のドーパミン作動性活性が増加すると考えられています。

当レポートでは、主要7ヶ国におけるパーキンソン病治療薬のXADAGO市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 パーキンソン病におけるXADAGOの概要

• 製品の詳細
• 臨床開発
• 規制のマイルストーン
• その他の発達活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 XADAGO市場評価

• パーキンソン病におけるXADAGOの市場の見通し
• 主要7ヶ国分析
  • 主要7ヶ国のパーキンソン病治療におけるXADAGOの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: XADAGO, Clinical Trial Description, 2023
• Table 2: XADAGO, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: XADAGO Market Size in the 7MM, in USD million (2019-2032)
• Table 6: XADAGO Market Size in the US, in USD million (2019-2032)
• Table 7: XADAGO Market Size in Germany, in USD million (2019-2032)
• Table 8: XADAGO Market Size in France, in USD million (2019-2032)
• Table 9: XADAGO Market Size in Italy, in USD million (2019-2032)
• Table 10: XADAGO Market Size in Spain, in USD million (2019-2032)
• Table 11: XADAGO Market Size in the UK, in USD million (2019-2032)
• Table 12: XADAGO Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: XADAGO Market Size in the 7MM, USD million (2019-2032)
• Figure 2: XADAGO Market Size in the United States, USD million (2019-2032)
• Figure 3: XADAGO Market Size in Germany, USD million (2019-2032)
• Figure 4: XADAGO Market Size in France, USD million (2019-2032)
• Figure 5: XADAGO Market Size in Italy, USD million (2019-2032)
• Figure 6: XADAGO Market Size in Spain, USD million (2019-2032)
• Figure 7: XADAGO Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: XADAGO Market Size in Japan, USD million (2019-2032)

"XADAGO Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about XADAGO for Parkinson's disease in the seven major markets. A detailed picture of the XADAGO for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the XADAGO for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the XADAGO market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.

Drug Summary:

XADAGO tablets contain safinamide as the mesylate salt. Safinamide mesylate is (S)-2-[[4-[(3-fluorophenyl) methoxy] phenyl] methyl] aminopropanamide methanesulfonate (1:1). XADAGO is available as 50 mg and 100 mg film-coated tablets for oral administration. Each tablet contains 65.88 mg or 131.76 mg of safinamide mesylate, equivalent to 50 mg or 100 mg, respectively, of the safinamide-free base. The tablets also contain the following inactive ingredients: colloidal silicon dioxide, crospovidone, hypromellose, iron oxide (red), magnesium stearate, microcrystalline cellulose, polyethylene glycol 6000, potassium aluminum silicate, and titanium dioxide.

Dosage and administration

• It is started with 50 mg administered orally once daily at the same time of day; after 2 weeks, the dose may be increased to 100 mg once daily, based on individual need and tolerability.
• In hepatic impairment, patient dosage should not exceed 50 mg once daily. It is contraindicated in patients with severe hepatic impairment.

Mechanism of action

The precise mechanism by which XADAGO exerts its effect in Parkinson's disease is unknown. XADAGO is an inhibitor of monoamine oxidase B (MAO-B). Inhibition of MAO-B activity, by blocking the catabolism of dopamine, is thought to result in an increase in dopamine levels and a subsequent increase in dopaminergic activity in the brain.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the XADAGO description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
• Elaborated details on XADAGO regulatory milestones and other development activities have been provided in this report.
• The report also highlights the XADAGO research and development activities in Parkinson's disease across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around XADAGO.
• The report contains forecasted sales of XADAGO for Parkinson's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
• The report also features the SWOT analysis with analyst views for XADAGO in Parkinson's disease.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

XADAGO Analytical Perspective by DelveInsight

• In-depth XADAGO Market Assessment

This report provides a detailed market assessment of XADAGO for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• XADAGO Clinical Assessment

The report provides the clinical trials information of XADAGO for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence XADAGO dominance.
• Other emerging products for Parkinson's disease are expected to give tough market competition to XADAGO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of XADAGO in Parkinson's disease.
• Our in-depth analysis of the forecasted sales data of XADAGO from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the XADAGO in Parkinson's disease.

Key Questions:

• What is the product type, route of administration and mechanism of action of XADAGO?
• What is the clinical trial status of the study related to XADAGO in Parkinson's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the XADAGO development?
• What are the key designations that have been granted to XADAGO for Parkinson's disease?
• What is the forecasted market scenario of XADAGO for Parkinson's disease?
• What are the forecasted sales of XADAGO in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to XADAGO for Parkinson's disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?

Table of Contents

1. Report Introduction

2. XADAGO Overview in Parkinson's disease

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and Efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. XADAGO Market Assessment

• 5.1. Market Outlook of XADAGO in Parkinson's disease
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of XADAGO in the 7MM for Parkinson's disease
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of XADAGO in the United States for Parkinson's disease
  • 5.3.2. Market Size of XADAGO in Germany for Parkinson's disease
  • 5.3.3. Market Size of XADAGO in France for Parkinson's disease
  • 5.3.4. Market Size of XADAGO in Italy for Parkinson's disease
  • 5.3.5. Market Size of XADAGO in Spain for Parkinson's disease
  • 5.3.6. Market Size of XADAGO in the United Kingdom for Parkinson's disease
  • 5.3.7. Market Size of XADAGO in Japan for Parkinson's disease

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options